Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus CLINDAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus CLINDAGEL.
BENSULFOID vs CLINDAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, disrupting peptide chain initiation. It may also exhibit anti-inflammatory and immunomodulatory effects via inhibition of neutrophil chemotaxis and phagocytosis.
Bensulfoid: not a recognized drug. No data available.
Apply thin layer to affected area twice daily.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
2-3 hours in patients with normal renal function; clinically significant accumulation may occur in severe hepatic impairment.
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Approximately 10% of the dose is excreted renally as unchanged drug; the remainder is hepatically metabolized and excreted in bile and feces. Renal clearance accounts for <1% of total clearance.
Category C
Category C
Topical Antibiotic
Topical Antibiotic